Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

[59] Thus, there are not enough data to support the use of HER2 as a prognostic marker, or as a predictor for specific chemotherapy protocols/endocrine therapy or for routine detection of serum ...